Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11283213 | 0.84 | TSHR (0.55) | L3MBTL1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL6836054 | 0.83 | NPC1 (0.58) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL6836087 | 0.83 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL13985770 | 0.77 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL15025300 | 0.77 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL13985577 | 0.76 | NPC1 (0.55) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL13985581 | 0.75 | NPC1 (0.53) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL4532507 | 0.75 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL27621187 | 0.75 | MEN1 (0.57) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL13985569 | 0.74 | NPC1 (0.52) | L3MBTL1ALDH1A1SMN1; SMN2NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| EP-1537081-B1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1537081-A1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer HealthCare AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020412-A1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020412-A1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| US-4038399-A | 1,4-DIHYDROPYRIDINE CARBOXYLIC ACID ESTERS USEFUL AS CORONARY VESSEL DILATORS AND ANTI-HYPERTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | disclosed |
| US-4031104-A | ANTIHYPERTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-06-21 | — | — | US | disclosed |
| US-3996234-A | CORONARY VESSEL DILATORS, HYPOTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-07 | — | — | US | disclosed |
| US-3974275-A | 1,4-Dihydropyridine carboxylic acid esters useful as coronary vessel dilators and anti-hypertensives | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | SERPINB1, ELANE, MPO | L3MBTL1 4487/4885ALDH1A1 400/4885SMN1; SMN2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.